Merus N.V. has announced interim clinical data from its ongoing phase 2 trial evaluating the bispecific antibody petosemtamab in metastatic colorectal cancer (mCRC). According to the company, the study investigates petosemtamab in combination with standard of care FOLFOX or FOLFIRI in first- and second-line mCRC, as well as petosemtamab monotherapy in third-line or later settings. Reported results include a 100% response rate in first-line left-sided mCRC (n=8) and a 62% response rate in second-line left- and right-sided mCRC (n=13), with both confirmed and unconfirmed responses. No significant new safety signals or overlapping toxicities were identified. These data will be presented in a plenary session by Dr. Moh'd Khushman at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 24, 2025. Full presentations will be made available on the Merus website as they become available at the conference.